XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Pay vs Performance Disclosure - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure [Table]      
Pay vs Performance [Table Text Block]

Value of Initial Fixed $100 Investment Based on:

Year

Summary Compensation Table Total for PEO (1)

Compensation Actually Paid to PEO (2)

Average Summary Compensation Table Total for Non-PEO NEOs (3)

Average Compensation Actually Paid to Non-PEO NEOs (3)

Coherus Total Shareholder Return
(TSR) (4)

Peer Group TSR (5)

Net Income (Loss)

Net Product Revenue
(Company-Selected Measure) (6)

(a)

(b)($)

(c)($)

(d)($)

(e)($)

(f)($)

(g)($)

(h)($ in 000's)

(i)($ in 000's)

2022

6,866,396

212,826

2,122,124

470,265

(56)

11

(291,754)

210,760

2021

8,594,495

6,461,745

2,449,597

2,031,913

(11)

25

(287,100)

326,509

2020

7,278,761

8,381,980

2,035,344

2,408,072

(3)

26

132,244

475,824

(1)Represents total compensation paid to the principal executive officer, or PEO, Mr. Dennis Lanfear, as reflected in the Summary Compensation Table.

(2)The following table sets forth the adjustments made during each year presented to arrive at CAP to our PEO during each year:

2022

2021

2020

($)

($)

($)

Summary Compensation Table (SCT) Total Compensation

6,866,396

8,594,495

7,278,761

Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT

(5,071,908)

(6,730,275)

(5,454,150)

Fair value as of year-end of equity awards granted during the year that remain unvested

1,795,132

3,351,633

3,953,739

Change in fair value of prior years' equity awards that remain unvested as of year-end

(2,186,702)

(576,558)

1,510,655

Fair value on vesting date for awards granted and vested in the same year

433,008

2,291,315

1,275,275

Change in fair value from prior year-end to vesting date of prior years' awards that vested during year

(1,623,100)

(468,865)

(182,300)

Compensation Actually Paid (CAP)

212,826

6,461,745

8,381,980

(3)The following table sets forth the adjustments made during each year presented to arrive at CAP to our non-PEO NEOs during each year:

2022

2021

2020

($)

($)

($)

Average SCT Total for Non-PEO NEOs

2,122,124

2,449,597

2,035,344

Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT

(1,372,424)

(1,829,098)

(1,235,831)

Fair value as of year-end of equity awards granted during the year that remain unvested

537,826

1,286,137

1,037,351

Change in fair value of prior years' equity awards that remain unvested as of year-end

(550,147)

(108,942)

439,657

Fair value on vesting date for awards granted and vested in the same year

86,062

294,903

159,400

Change in fair value from prior year-end to vesting date of prior years' awards that vested during year

(353,176)

(60,684)

(27,849)

Average CAP to Non-PEO NEOs

470,265

2,031,913

2,408,072

The non-PEO NEOs included in average compensation shown in columns (d) and (e) above are as follows:

2022

2021

2020

McDavid Stilwell

Jean-Frederic Viret

Jean-Frederic Viret

Vladimir Vexler, Ph.D.

McDavid Stilwell

Vincent Anicetti

Vincent Anicetti

Vladimir Vexler, Ph.D.

Vladimir Vexler, Ph.D.

(4)Total Shareholder Return, or TSR, represents the cumulative growth of a hypothetical $100 investment in the Company made as of December 31, 2019, reflected as of the end of each respective year.

(5)Peer group TSR represents the cumulative growth of a hypothetical $100 investment made as of December 31, 2019 in the Nasdaq Biotechnology Index, which we also use for purposes of the stock performance graph included in our Annual Report for the year ended December 31, 2022, reflected as of the end of each respective year.

(6)SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (that is not TSR or net income) used by the Company to link the CAP of our NEOs, for the most recently completed fiscal year, to our performance. We selected Net Product Revenue as this measure for 2022 as reflected in column (i) in the first table above. Net product revenue is a Generally Accepted Accounting Principle measure reported in the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.
   
Company Selected Measure Name Net Product Revenue    
Named Executive Officers, Footnote [Text Block]
(1)Represents total compensation paid to the principal executive officer, or PEO, Mr. Dennis Lanfear, as reflected in the Summary Compensation Table.

The non-PEO NEOs included in average compensation shown in columns (d) and (e) above are as follows:

2022

2021

2020

McDavid Stilwell

Jean-Frederic Viret

Jean-Frederic Viret

Vladimir Vexler, Ph.D.

McDavid Stilwell

Vincent Anicetti

Vincent Anicetti

Vladimir Vexler, Ph.D.

Vladimir Vexler, Ph.D.

   
Peer Group Issuers, Footnote [Text Block]

(5)Peer group TSR represents the cumulative growth of a hypothetical $100 investment made as of December 31, 2019 in the Nasdaq Biotechnology Index, which we also use for purposes of the stock performance graph included in our Annual Report for the year ended December 31, 2022, reflected as of the end of each respective year.
   
PEO Total Compensation Amount $ 6,866,396 $ 8,594,495 $ 7,278,761
PEO Actually Paid Compensation Amount $ 212,826 6,461,745 8,381,980
Adjustment To PEO Compensation, Footnote [Text Block]

(2)The following table sets forth the adjustments made during each year presented to arrive at CAP to our PEO during each year:

2022

2021

2020

($)

($)

($)

Summary Compensation Table (SCT) Total Compensation

6,866,396

8,594,495

7,278,761

Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT

(5,071,908)

(6,730,275)

(5,454,150)

Fair value as of year-end of equity awards granted during the year that remain unvested

1,795,132

3,351,633

3,953,739

Change in fair value of prior years' equity awards that remain unvested as of year-end

(2,186,702)

(576,558)

1,510,655

Fair value on vesting date for awards granted and vested in the same year

433,008

2,291,315

1,275,275

Change in fair value from prior year-end to vesting date of prior years' awards that vested during year

(1,623,100)

(468,865)

(182,300)

Compensation Actually Paid (CAP)

212,826

6,461,745

8,381,980

   
Non-PEO NEO Average Total Compensation Amount $ 2,122,124 2,449,597 2,035,344
Non-PEO NEO Average Compensation Actually Paid Amount $ 470,265 2,031,913 2,408,072
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
(3)The following table sets forth the adjustments made during each year presented to arrive at CAP to our non-PEO NEOs during each year:

2022

2021

2020

($)

($)

($)

Average SCT Total for Non-PEO NEOs

2,122,124

2,449,597

2,035,344

Deduct for amounts reported under the "Stock Awards" and "Option Awards" in the SCT

(1,372,424)

(1,829,098)

(1,235,831)

Fair value as of year-end of equity awards granted during the year that remain unvested

537,826

1,286,137

1,037,351

Change in fair value of prior years' equity awards that remain unvested as of year-end

(550,147)

(108,942)

439,657

Fair value on vesting date for awards granted and vested in the same year

86,062

294,903

159,400

Change in fair value from prior year-end to vesting date of prior years' awards that vested during year

(353,176)

(60,684)

(27,849)

Average CAP to Non-PEO NEOs

470,265

2,031,913

2,408,072

   
Compensation Actually Paid vs. Total Shareholder Return [Text Block]

Graphic

   
Compensation Actually Paid vs. Net Income [Text Block]

Graphic

   
Compensation Actually Paid vs. Company Selected Measure [Text Block]

Graphic

   
Total Shareholder Return Vs Peer Group [Text Block]

Graphic

   
Tabular List [Table Text Block]

FINANCIAL PERFORMANCE MEASURE

The following financial performance measure represents the most important financial measure used to link compensation actually paid to the NEOs for 2022 to Company performance: Net Product Revenue.

   
Total Shareholder Return Amount $ (56) (11) (3)
Peer Group Total Shareholder Return Amount 11 25 26
Net Income (Loss) $ (291,754,000) $ (287,100,000) $ 132,244,000
Company Selected Measure Amount 210,760,000 326,509,000 475,824,000
PEO Name Mr. Dennis Lanfear    
Measure [Axis]: 1      
Pay vs Performance Disclosure [Table]      
Measure Name Net Product Revenue    
Non-GAAP Measure Description [Text Block]

(6)SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (that is not TSR or net income) used by the Company to link the CAP of our NEOs, for the most recently completed fiscal year, to our performance. We selected Net Product Revenue as this measure for 2022 as reflected in column (i) in the first table above. Net product revenue is a Generally Accepted Accounting Principle measure reported in the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.
   
PEO [Member] | Deduct for amounts reported under the "Stock Awards" and Option Awards" in the SCT      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ (5,071,908) $ (6,730,275) $ (5,454,150)
PEO [Member] | Fair value as of year-end of equity awards granted during the year that remain unvested      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 1,795,132 3,351,633 3,953,739
PEO [Member] | Change in fair value of prior years' equity awards that remain unvested as of year-end      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (2,186,702) (576,558) 1,510,655
PEO [Member] | Fair value on vesting date for awards granted and vested in the same year      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 433,008 2,291,315 1,275,275
PEO [Member] | Change in fair value from prior year-end to vesting date of prior years' awards that vested during year      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (1,623,100) (468,865) (182,300)
Non-PEO NEO [Member] | Deduct for amounts reported under the "Stock Awards" and Option Awards" in the SCT      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (1,372,424) (1,829,098) (1,235,831)
Non-PEO NEO [Member] | Fair value as of year-end of equity awards granted during the year that remain unvested      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 537,826 1,286,137 1,037,351
Non-PEO NEO [Member] | Change in fair value of prior years' equity awards that remain unvested as of year-end      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (550,147) (108,942) 439,657
Non-PEO NEO [Member] | Fair value on vesting date for awards granted and vested in the same year      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 86,062 294,903 159,400
Non-PEO NEO [Member] | Change in fair value from prior year-end to vesting date of prior years' awards that vested during year      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ (353,176) $ (60,684) $ (27,849)